NCT Number: NCT05774561
This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
Olomouc, 77900, Czechia
Location status: Recruiting
Marian Hajduch, MD, PhD.
CONTACT
Radovan Pilka, prof. MD,PhD
PRINCIPAL_INVESTIGATOR
Richard Salzman, MD, PhD.
PRINCIPAL_INVESTIGATOR
Vladimira Koudelakova, MSc., PhD.
CONTACT
Although the cancers associated with human papillomavirus (HPV) infection are currently almost entirely preventable, a significant part of the Czech population suffers from these diseases. The most common HPV-associated cancers are cervical cancer (CC) and oropharyngeal cancer (OPC). In these, the severe problem is successful monitoring of the treatment effectiveness and early disease recurrence detection. It is, therefore, necessary to find a non-invasive method that could specifically and timely identify patients at risk of recurrence and thus enable patients with quality and less burdensome medical care. The use of liquid biopsies (LB), which the study focuses on, looks most promising.
This study is divided into two arms, with each arm including both prospective and retrospective parts. Into prospective parts will be enrolled only newly diagnosed CC/HSIL (high-grade cervical intraepithelial lesions) or OPC patients. In contrast, the retrospective part will enroll patients in post-treatment follow-up. In both study arms, fresh tumor tissues will be sampled from patients in prospective parts before treatment, and archived Formalin Fixed Paraffin Embedded (FFPE) tissue samples will be obtained from patients of retrospective parts.
Regarding the liquid biopsies, pre & post-treatment sampling of LB will be performed. Subsequently, regular sample acquisition will be performed during follow-up according to the standard medical practice in both prospective and retrospective parts. Oropharyngeal swabs, gargle lavage,exhaled breath condensate (EBC), and blood samples will be collected from OPC patients. Blood collection and self-sampling of cervicovaginal swabs will be performed in patients with CC/HSIL. All samples, excluding blood samples, will be tested for the presence of the most prevalent high-risk and low-risk HPV genotypes. The circulating tumor (ct) HPV DNA will be monitored in blood samples. Additionally, the mutation profile of the primary tumors will be examined in fresh and FFPE samples.
The dynamics of HPV DNA will be monitored throughout all follow-up samples and correlated with the obtained clinical data. A created panel of frequently altered genes will be used for alterations monitoring in liquid biopsies. In the final analysis of laboratory and clinical results, we assume a finding of a clinically usable algorithm that could predict the risk of disease recurrence for a particular patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.
Exclusion criteria
No exclusion criteria are set.
Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
Time frame: 4 years
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups.
Time frame: 4 years
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups.
Time frame: 4 years
Correlation of plasmatic ct HPV DNA level with cancer patient´s prognosis.
Time frame: 4 years
Correlation of plasmatic ct HPV DNA level with patient´s prognosis
Time frame: 4 years
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis.
Time frame: 4 years
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis.
Contact information is provided by the study sponsor or research team.
Marian Hajduch, MD., PhD.
CONTACT
Vladimira Koudelakova, MSc, Ph.D.
CONTACT
The Institute of Molecular and Translational Medicine, Czech Republic
Other
Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04226313
Cervical Cancer, Cervical Dysplasia
Olomouc, Czechia
View Trial DetailsNCT06915779
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Vancouver, British Columbia, Canada
View Trial DetailsNCT04133610
Cervical Cancer, Cervical Dysplasia
Frýdek-Místek, Czechia
View Trial DetailsNCT03346915
Anal Cancer, Anus Diseases
Boston, Massachusetts, United States
View Trial Details